Abstract
A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 169-172 |
Number of pages | 4 |
Journal | Prostaglandins and Other Lipid Mediators |
Volume | 75 |
Issue number | 1-4 |
DOIs | |
State | Published - Jan 2005 |
Keywords
- Cyclooxygenase-2 inhibition
- Experimental trial
ASJC Scopus subject areas
- Biochemistry
- Physiology
- Pharmacology
- Cell Biology